ArticleProstate cancer and prostatic diseases2023

Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.

Corbin J Eule et al.PubMed ↗Publisher ↗

No numbers read from the abstract.